Rapport Therapeutics, Inc. SEC filings RAPP

Rapport Therapeutics, Inc. has 253 filings in SEC EDGAR's recent list, going back to Mar 27, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.

Rapport Therapeutics, Inc. SEC filings
Form Description Filed Period
424B5 Prospectus supplement Oct 30, 2026 —
424B5 Prospectus supplement Oct 30, 2026 —
FWP Free writing prospectus Oct 28, 2026 —
FWP Free writing prospectus Oct 28, 2026 —
FWP Free writing prospectus Oct 28, 2026 —
FWP Free writing prospectus Oct 28, 2026 —
424B5 Prospectus supplement Oct 27, 2026 —
424B5 Prospectus supplement Oct 27, 2026 —
S-3ASR Automatic shelf registration Mar 10, 2026 —
S-8 Employee stock plan registration Mar 10, 2026 —
424B5 Prospectus supplement Jan 7, 2026 —
424B5 Prospectus supplement Sep 10, 2025 —
424B5 Prospectus supplement Sep 8, 2025 —
S-3 Shelf registration Jul 1, 2025 —
S-3 Shelf registration Jul 1, 2025 —
S-8 Employee stock plan registration Mar 11, 2025 —
S-8 Employee stock plan registration Jun 7, 2024 —
424B4 Prospectus Jun 7, 2024 —
S-1/A Amended registration statement Jun 3, 2024 —
S-1 Registration statement May 17, 2024 —

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RAPP (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2012593
Former names
Rapport Therapeutics, Inc. (until Nov 4, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.